Janett Flores Pérez

Prof. Janett Flores Pérez

Laboratorio de Farmacología, Instituto Nacional de Pediatria, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
EVErendira Vicencio-Rosas
Erendira Vicencio-Rosas
MPMaría Gabriela Pérez-Guillé
María Gabriela Pérez-Guillé
CPCarmen Flores Pérez
Carmen Flores Pérez
JPJanett Flores Pérez
Janett Flores Pérez
FTFrancisca Trujillo-Jiménez
Francisca Trujillo-Jiménez
Juan Luis Chávez PachecoJuan Luis Chávez Pacheco
Juan Luis Chávez Pacheco

Introduction:
The usual management of moderate to severe pain is based on the use of ­opioids. Buprenorphine (BPN) is an opioid with an analgesic potency 50 times greater than that of morphine. It is widely used in various pain models and has demonstrated efficacy and safety in adult patients; however, there are insufficient clinical trials in pediatric populations. Purpose: The aim of this study was to perform an updated meta-analysis on the implementation of BPN in the treatment of pain in the pediatric population. Methods: A bibliographic search was carried out in different biomedical databases to identify scientific papers and clinical trials with evidence of BPN use in children and adolescents. Results: A total of 89 articles were found, of which 66 were selected. Analysis of these items revealed additional sources, and the final review included a total of 112 publications. Conclusion: Few studies were found regarding the efficacy and safety of BPN use in children. In recent years, the use of this drug in the pediatric population has become widespread, so it is imperative to perform clinical trials and pharmacological and pharmacovigilance studies, which will allow researchers to develop dosage schemes based on the evidence and minimize the risk of adverse effects.

27 September 2010 in Biomedical Chromatography
Verified
Journal Article
Closed access
PDF file
CFCarmen Flores‐Pérez
Carmen Flores‐Pérez
JCJuan Luis Chávez‐Pacheco
Juan Luis Chávez‐Pacheco
BRBlanca Ramírez‐Mendiola
Blanca Ramírez‐Mendiola
RARadamés Alemón‐Medina
Radamés Alemón‐Medina
RGRaquel García‐Álvarez
Raquel García‐Álvarez
JPJanett Flores Pérez
Janett Flores Pérez

6 January 2004 in Biopharmaceutics & Drug Disposition
Verified
Journal Article
Closed access
PDF file
HOHugo Juarez Olguin
Hugo Juarez Olguin
JPJanett Flores Pérez
Janett Flores Pérez
IAIsmael Lares Asseff
Ismael Lares Asseff
AAArturo Loredo Abdalá
Arturo Loredo Abdalá
LRLuis Carbajal Rodríguez
Luis Carbajal Rodríguez

1 January 2003 in Chronobiology International
Verified
Journal Article
Closed access
JPJanett Flores Pérez
Janett Flores Pérez
HOHugo Juárez Olguín
Hugo Juárez Olguín
CPCarmen Flores Pérez
Carmen Flores Pérez
GGGabriela Pérez Guillé
Gabriela Pérez Guillé
APAdrián Guillé Pérez
Adrián Guillé Pérez
IAIsmael Lares Asseff
Ismael Lares Asseff
The present study was undertaken to determine if differences exist in the pharmacokinetic parameters of oral ranitidine caused by gender and stage of the menstrual cycle. The study was performed in...

1 February 1999 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
ILIsmael Lares-Asseff
Ismael Lares-Asseff
JPJanett Flores Pérez
Janett Flores Pérez
HJHugo Juárez-Olguín
Hugo Juárez-Olguín
MRMartha Ramírez-Lacayo
Martha Ramírez-Lacayo
ALArturo Loredo-Abdalá
Arturo Loredo-Abdalá
LCLuis Carbajal-Rodríguez
Luis Carbajal-Rodríguez
Background: It is unknown whether nutritional status associated with autoimmune disease alters the pharmacokinetics of acetylsalicylic acid (ASA) and its metabolites. Objective: We studied the effects of the nutritional status of children with autoimmune disease on the disposition of ASA and its metabolites. Design: A prospective, open-label study was performed with 21 children aged 3–15 y who required ASA therapy. Children received 25 mg ASA/kg orally. Blood samples were drawn before and 0.5, 1.0, 2.0, 4.0, 8.0, 12.0, and 24.0 h after ASA administration; urine samples were collected at different intervals. ASA and its metabolites were measured in plasma and urine. Nutritional status was assessed previously. Results: The ASA maximum plasma concentration, area under the curve, and total clearance were significantly lower in underweight children than in normal-weight children. The elimination rate constants of gentisic acid (GA), salicyluric acid (SUA), and salicylic acid (SA) in plasma were slower for underweight children than for normal-weight children. The distribution volume of SUA increased significantly (r = 0.92) when the deficit percentage in weight-for-height increased. Underweight children excreted less GA and SA, but more SUA, than did normal-weight children. Conclusions: These observations suggest a decrease in the hydrolysis and oxidative reactions of the metabolic pathway of ASA and its metabolites in underweight children. The study illustrates the need for pharmacokinetic data to establish the individual doses of drugs, particularly in conditions that alter nutritional status.

25 September 2003 in Journal of Chromatography B
Verified
Journal Article
Closed access
CPCarmen Flores Pérez
Carmen Flores Pérez
HOHugo Juárez Olguı́n
Hugo Juárez Olguı́n
JPJanett Flores Pérez
Janett Flores Pérez
ALAlejandra Toledo López
Alejandra Toledo López
IAIsmael Lares Asseff
Ismael Lares Asseff
CGCarlos Alvarez Garcı́a
Carlos Alvarez Garcı́a